{"id":90492,"date":"2026-11-10T19:23:00","date_gmt":"2026-11-10T19:23:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=90492"},"modified":"2026-11-11T02:11:43","modified_gmt":"2026-11-11T02:11:43","slug":"idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/","title":{"rendered":"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight"},"content":{"rendered":"<p><em>DelveInsight&#8217;s report sizes the Idiopathic Inflammatory Myositis market at USD 714 million across the 7MM in 2025, with a significant 16.8% CAGR forecast through 2036. This growth is driven by the high unmet medical need, increasing disease awareness, advancements in diagnostic capabilities, and the growing focus on developing targeted therapies to address disease heterogeneity and improve patient outcomes. Additionally, the expanding clinical development pipeline, including Dazukibart (Pfizer), Nerandomilast (Boehringer Ingelheim), CABA-201 (Cabaletta Bio), Ulviprubart (ABC008; Abcuro), and other targeted treatment candidates, is expected to drive market growth across the 7MM from 2026\u20132036, with significant commercial opportunities as innovative therapies advance toward potential approval and launch.<\/em><\/p>\n<p align=\"justify\" style=\"text-align:justify;\">New York, USA, Nov.  10, 2026  (GLOBE NEWSWIRE) &#8212; <b>Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight<\/b><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b><i>DelveInsight&#8217;s report sizes the Idiopathic Inflammatory Myositis market at USD 714 million across the 7MM in 2025, with a significant 16.8% CAGR forecast through 2036. This growth is driven by the high unmet medical need, increasing disease awareness, advancements in diagnostic capabilities, and the growing focus on developing targeted therapies to address disease heterogeneity and improve patient outcomes. Additionally, the expanding clinical development pipeline, including Dazukibart (Pfizer), Nerandomilast (Boehringer Ingelheim), CABA-201 (Cabaletta Bio), Ulviprubart (ABC008; Abcuro), and other targeted treatment candidates, is expected to drive market growth across the 7MM from 2026\u20132036, with significant commercial opportunities as innovative therapies advance toward potential approval and launch.<\/i><\/b><\/p>\n<p align=\"justify\" style=\"text-align:justify;\">Recently published Idiopathic Inflammatory Myositis Market Insights report includes a comprehensive understanding of current treatment practices, idiopathic inflammatory myositis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].\u00a0<\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Idiopathic Inflammatory Myositis Market Summary<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">The market size for idiopathic inflammatory myositis was found to be <b>USD 714 million<\/b> in the 7MM in 2025.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The United States accounted for about <b>55%<\/b> of the 7MM market in 2025, the largest share of any market covered.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The total number of diagnosed prevalent cases of IIM in the 7MM ranges approximately<b> 198,000<\/b> cases in 2025. This growth is primarily driven by population aging, improved disease recognition, greater diagnostic awareness, and enhanced access to specialist care.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Leading idiopathic inflammatory myositis companies, such as <b>Pfizer, Boehringer Ingelheim, Cabaletta Bio, Abcuro, Amgen, Novartis Pharmaceuticals, Lakefront Biotherapeutics, Argenx, AstraZeneca, RESTEM, Gilead Sciences,<\/b> and others, are developing new idiopathic inflammatory myositis treatment drugs that can be available in the idiopathic inflammatory myositis market in the coming years.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The promising idiopathic inflammatory myositis therapies in clinical trials include <b>Dazukibart, Nerandomilast, CABA-201, Ulviprubart (ABC008), Daxdilimab, Rapcabtagene autoleucel, GLPG3667, Efgartigimod (VYVGART), Anifrolumab (SAPHNELO), RESTEM-L (ULSC), Gamgertamig (OM336), <\/b>and others.<\/li>\n<\/ul>\n<p align=\"justify\" style=\"text-align:justify;\">Download the free sample page to discover new treatments for idiopathic inflammatory myositis @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j1krfWvaFUSKLGh0wPHRa-zxPfR3qsabsNysATwdVNal1Z16K99VOEV2VyCz-wEv0E6adIq6aDnAh0Pce573L1CHwQhqPcEOrpUQi8Yj_JF6XsfkS8XM0glCkckHFuOu4jNBk_9NO1XAr-fsVxfSA8NRuW9jV0_P5-EBXpaBqKosu1HgNUd1SKywP5k3tN9KZHxnJoGGthlV4mKavbqgdo76WqUHwhqHefyEx3zE8WhnNDLN1on7qZ-VUt0m0Xd6RiM1PgEpTfIddCywDW7Eite-JcU5G_AnuNIhw0W93NOCnklWyO00145iHuKx5yETiiQh0KwtcuSh9WN90-MR_g==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>https:\/\/www.delveinsight.com\/report-store\/idiopathic-inflammatory-myositis-market<\/b><\/a><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><i>As per Aparna Thakur, Project Manager of Forecasting at DelveInsight, brepocitinib (LISRAYA) is expected to account for ~17% of the IIM market in 2036, supported by its first-in-class positioning as an oral targeted therapy for dermatomyositis, increasing physician familiarity with JAK\/TYK2 inhibition, convenient once-daily oral administration, and the substantial unmet need for effective steroid-sparing treatment options in dermatomyositis.<\/i><\/p>\n<p align=\"justify\"><i><img loading=\"lazy\" decoding=\"async\" alt=\"\" data-mce-style=\"display: block; margin-left: auto; margin-right: auto;\" height=\"420\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/16f1fbb2-71c4-4e99-b354-90212be81068\/idiopathic-inflammatory-myositis-market.jpg\" style=\"display:block; margin-left:auto; margin-right:auto;\" width=\"800\" data-dpi=\"96\" data-filename=\"Idiopathic-Inflammatory-Myositis-Market.jpg\" \/><br \/><\/i><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Key Factors Driving the Growth of the Idiopathic Inflammatory Myositis Market\u00a0<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><b>Rising Disease Awareness and Improved Diagnosis: <\/b>Growing awareness of idiopathic inflammatory myositis (IIM), including dermatomyositis, polymyositis, and inclusion body myositis, is supporting earlier disease recognition. Advances in autoantibody testing, muscle imaging, and diagnostic techniques are helping improve disease identification and patient management.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Increasing Adoption of Targeted Therapies: <\/b>The limitations of conventional treatments, such as corticosteroids and immunosuppressants, are driving interest in targeted therapeutic approaches. Biologics and other immune-modulating agents offer opportunities to improve disease control, particularly among patients with refractory disease or inadequate responses to existing treatments.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Expanding Clinical Development Pipeline: <\/b>Ongoing research into novel mechanisms of action, including B-cell depletion, cytokine inhibition, and modulation of immune pathways, is strengthening the IIM drug development landscape. Clinical trials evaluating investigational therapies are expected to expand treatment options and support future market growth.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Growing Investment in Rare Disease Research: <\/b>Increasing investment by pharmaceutical and biotechnology companies in autoimmune and rare inflammatory diseases is supporting the development of novel IIM treatments. Orphan drug incentives, research collaborations, and advances in immunology are helping accelerate clinical development and potentially improve commercial opportunities.<\/li>\n<\/ul>\n<p align=\"justify\" style=\"text-align:justify;\">Download the report to understand the top emerging idiopathic inflammatory myositis drugs @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PxC8xcRYS_mrXzxxrCNhIJxsJUJjIQnlxmV6HxAMWboetSHyj_TA8mU3kOu2v6cEVmo0wQZ7nnl5x2q37TgrciN5dyvO3uieQ4j2jOf5bucFWC9kfGOEbn7pNlXUOV_ktD-goeEQZ0ZdUnod-EKiMUbb43b82RzbXcJo_zKbs3Jnzmd5i51EY_9mtRM-ruFQrowb_l2qGrbYvR6xIgBPBM7tUPlK4JNElPREWRvR43GvdKc9ciX2f84F1JD6WFJekwOhVyAhtxvCj5kSgP9AAjivNmmxiIK1lantUsV6Jyo=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Idiopathic Inflammatory Myositis Clinical Trials<\/b><\/a><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Idiopathic Inflammatory Myositis Market Analysis<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Treatment of idiopathic inflammatory myopathies continues to rely primarily on corticosteroids and conventional immunosuppressants, including methotrexate, azathioprine, mycophenolate mofetil, and tacrolimus, which are widely used across dermatomyositis, polymyositis, and related subtypes.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">However, inconsistent treatment responses, delayed therapeutic effects, disease relapse, and the cumulative toxicity associated with long-term corticosteroid and immunosuppressant use underscore the need for more effective steroid-sparing and subtype-specific treatment options.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The approved IIM treatment landscape remains relatively limited, with <b>intravenous immunoglobulin (IVIG)<\/b> and conventional immunosuppressive therapies forming the mainstay of treatment.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>OCTAGAM 10% (IVIG)<\/b> represents an important approved therapeutic option for adults with dermatomyositis.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The emerging IIM pipeline is becoming increasingly diverse, with investigational and targeted therapies addressing multiple mechanisms of action and disease subtypes.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Notable candidates include <b>nerandomilast, dazukibart, efgartigimod, anifrolumab (SAPHNELO), umbilical cord lining stem cells (ULSC), CABA-201, ulviprubart (ABC008), daxdilimab, and GLPG3667<\/b>, reflecting ongoing efforts to expand treatment options and address unmet clinical needs across the IIM spectrum.<\/li>\n<\/ul>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Idiopathic Inflammatory Myositis Competitive Landscape<\/b><\/p>\n<p align=\"justify\" style=\"text-align:justify;\">Some of the IIM drugs under development include <b>Dazukibart <\/b>(Pfizer), <b>Nerandomilast <\/b>(Boehringer Ingelheim), <b>CABA-201 <\/b>(Cabaletta Bio), <b>Ulviprubart <\/b>(ABC008; Abcuro), <b>Daxdilimab <\/b>(Amgen), <b>Rapcabtagene autoleucel<\/b> (Novartis Pharmaceuticals), <b>GLPG3667 <\/b>(Lakefront Biotherapeutics), <b>Efgartigimod <\/b>(VYVGART; Argenx), <b>Anifrolumab <\/b>(SAPHNELO; AstraZeneca), <b>RESTEM-L<\/b> (ULSC; RESTEM), <b>Gamgertamig <\/b>(OM336; Gilead Sciences and Lakefront Biotherapeutics), and others.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Pfizer\u2019s Dazukibart<\/b> is an investigational monoclonal antibody targeting interferon-beta (IFN-\u03b2), being developed by Pfizer for idiopathic inflammatory myopathies (IIM), particularly dermatomyositis and polymyositis. It selectively binds to and neutralizes IFN-\u03b2, aiming to inhibit IFN-\u03b2-mediated inflammatory signaling pathways associated with muscle and skin manifestations of IIM. Dazukibart is currently undergoing Phase III clinical development for dermatomyositis and polymyositis.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Argenx\u2019s efgartigimod<\/b> is an investigational neonatal Fc receptor (FcRn) antagonist being evaluated for IIM, including dermatomyositis and immune-mediated necrotizing myopathy (IMNM). By selectively binding to and blocking FcRn, efgartigimod reduces the recycling of immunoglobulin G (IgG) antibodies, thereby lowering their circulating levels, including those of disease-causing autoantibodies. This mechanism may help mitigate autoimmune-mediated muscle inflammation and tissue damage. Efgartigimod is currently being evaluated in Phase III clinical trials for active IIM.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Amgen\u2019s Daxdilimab<\/b> is a fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7) that works by depleting specific dendritic cell populations. It is under investigation for the treatment of dermatomyositis and anti-synthetase inflammatory myositis. Daxdilimab has completed Phase II clinical evaluation.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\">The anticipated launch of these emerging therapies are poised to transform the idiopathic inflammatory myositis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the idiopathic inflammatory myositis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\">See the idiopathic inflammatory myositis pipeline by phase and company @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PxC8xcRYS_mrXzxxrCNhIJxsJUJjIQnlxmV6HxAMWbpxwZb_-PLhntS-McmqhFLM4WgJKRqmdHxdkLoq51rylq2zp3cWujSCmEhsv4cXQP71nQjDOVombO3RJZUvXd1-Mk2korfPJs9K4OwrY4tUY5D8EeHasnRah6dIJMB1LD6rZtzWShaX-qZJ445Qtrgca27Mhm7SiaunFYr9H6uMo5Em_sRo_jiJJ8OP1zwMwFEIBNavtPl6p3pu5FW2A1i1sXEWmN7aoqmk6ALK-bH7i_tRpuwOcqcIRmhmFsXIDPg=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Idiopathic Inflammatory Myositis Medications<\/b><\/a><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Recent Developments in the Idiopathic Inflammatory Myositis Market\u00a0<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">In <b>September 2026, Nkarta <\/b>announced that NKX019 will be featured in an oral presentation at ACR Convergence 2026, highlighting preliminary safety, pharmacokinetics and pharmacodynamics, and clinical activity in IIM\/myositis from the Phase I\/II Ntrust studies. IIM-specific data are expected on November 8, 2026.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In<b> August 2026, Argenx<\/b> announced positive topline results from the Phase III ALKIVIA study evaluating efgartigimod alfa and hyaluronidase (VYVGART Hytrulo) in adults with autoimmune myositis, supporting its development as a potential treatment option for IIM.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>August 2026, <\/b>Rese-cel was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US FDA for generalized myasthenia gravis, building on its previous RMAT designation for myositis.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>August 2026, Lakefront Biotherapeutics<\/b> announced its half-year 2026 financial results and provided a second-quarter and post-period business update, reporting that GLPG3667 completed the Phase II GALARISSO study in dermatomyositis, including its 24-week open-label extension; the company is evaluating strategic options for the GLPG3667 program.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>July 2026, Fate Therapeutics<\/b> received FDA IND clearance for FT839, supporting its Phase I\/II development in IIM\/myositis.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In<b> June 2026, Argenx<\/b> announced the presentation of new data on efgartigimod alfa, including IV efgartigimod alfa and SC\/Hytrulo efgartigimod alfa with hyaluronidase, in autoimmune rheumatic diseases, including myositis, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress held in London.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>May 2026, Cabaletta Bio<\/b> announced plans to present multiple oral and poster presentations on rese-cel at the EULAR 2026 Congress (June 3\u20136, London), including the RESET-Myositis Phase I\/II study with longer-term follow-up data from patients with dermatomyositis and ASyS.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>April 2026, Cabaletta Bio<\/b> announced multiple manufacturing, translational, and clinical presentations on rese-cel at the ASGCT 2026 Annual Meeting, including a presentation on single-cell profiling of peripheral blood mononuclear cell (PBMC) subsets across the RESET-Myositis Phase I\/II trials.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>March 2026, Abcuro<\/b> presented Phase II\/III MUSCLE clinical study data for ulviprubart at the 6th Global Conference on Myositis (GCOM), supporting its development as an investigational treatment for IBM, a chronic autoimmune disease with no approved treatments.<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Idiopathic Inflammatory Myositis Market Report Metrics<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Details<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Study Period<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2022\u20132036<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Coverage<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Idiopathic Inflammatory Myositis Market CAGR<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">16.8%\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Idiopathic Inflammatory Myositis Market Size in 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">USD 714 Million<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Idiopathic Inflammatory Myositis Companies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Pfizer, Boehringer Ingelheim, Cabaletta Bio, Abcuro, Amgen, Novartis Pharmaceuticals, Lakefront Biotherapeutics, Argenx, AstraZeneca, RESTEM, Gilead Sciences, Octapharma, Mitsubishi Tanabe Pharma, Priovant Therapeutics, and others<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Idiopathic Inflammatory Myositis Therapies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dazukibart, Nerandomilast, CABA-201, Ulviprubart (ABC008), Daxdilimab, Rapcabtagene autoleucel, GLPG3667, Efgartigimod (VYVGART), Anifrolumab (SAPHNELO), RESTEM-L (ULSC), Gamgertamig (OM336), OCTAGAM 10%, VENOGLOBULIN-IH, LISRAYA, and others<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\" style=\"text-align:justify;\"><b>What\u2019s the Idiopathic Inflammatory Myositis Market Report Includes?<\/b><\/p>\n<p align=\"justify\" style=\"text-align:justify;\">DelveInsight&#8217;s Idiopathic Inflammatory Myositis Market Report delivers executive-level intelligence on the evolving market landscape, integrating epidemiology (IIM Diagnosed Prevalent Cases, Type-specific IIM Diagnosed Prevalent Cases, Age-specific IIM Diagnosed Prevalent Cases, Gender-specific IIM Diagnosed Prevalent Cases, Total Treated IIM Cases, and Total Relapsed\/Refractory IIM Cases), treatment practices, competitive dynamics, emerging therapies, and market forecasts across the major markets through 2036. Built on a rigorous methodology combining comprehensive secondary research, primary interviews with key opinion leaders and industry experts, and proprietary patient-based forecasting models, the report provides a reliable foundation for strategic planning. Designed for pharmaceutical and biotech executives, it enables informed decisions on portfolio strategy, business development, market entry, investment prioritization, and commercial planning.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\">Request a free sample @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PxC8xcRYS_mrXzxxrCNhIJxsJUJjIQnlxmV6HxAMWbrcyLMWhj7ivYMYCt7wOmcPhnHaiUduFv38z6lFiNq5DeUF5DRxh7BqX-7Q62XqCFe3yrHDp29Ml5Jwy--2_7DzSrWUCuXe1Ez7h59uIRuYqoMOyAEyd5cFwJEXD-Bg-LVy97-1aGyZwKQWPhB-Qb8vMWFMWag6cy-MWtwjN2gbruhdPiGPyf2lPp0FFOLJ5VMDEYsKvFn-ErqgBuMlp2Ip-lDB_HoJ6ruiaYENE-PQxsrH3QsauTsmASjTw8ftlkk=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Idiopathic Inflammatory Myositis Market Report<\/b><\/a><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Table of Contents<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">1<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Idiopathic Inflammatory Myositis Market Key Insights<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Idiopathic Inflammatory Myositis Market Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Executive Summary of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Events<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Market Forecast Methodology<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">IIM Market Overview at a Glance<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Landscape (Analysis by Phase, Route of Administration [RoA]), and Molecule Type)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Share (%) Distribution of IIM by Therapies in 2025 in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Share (%) Distribution of IIM by Therapies in 2036 in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Disease Background and Overview of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Classification<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Etiology and Risk Factors<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Pathophysiology of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Diagnosis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment and Management of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment Algorithm<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment Guidelines<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Patient Population of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Assumptions and Rationale<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Country-Level Summary of Diagnosed Prevalent IIM Cases in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">IIM Diagnosed Prevalent Cases in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">IIM Diagnosed Prevalent Cases by Type in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">IIM Diagnosed Prevalent Cases by Age in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">IIM Diagnosed Prevalent Cases by Gender in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Treated IIM Cases in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Relapsed\/Refractory IIM Cases in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">10<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Patient Journey of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Marketed Therapies of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Marketed Drugs Competitive Landscape of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">OCTAGAM 10% (Intravenous Immune Globulin [Human]): Octapharma\/Pfizer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Product Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Regulatory Milestones<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Developmental Activities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Summary of Pivotal Trial<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Safety and Efficacy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">VENOGLOBULIN-IH: Mitsubishi Tanabe Pharma<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Brepocitinib (LISRAYA): Priovant Therapeutics\/Pfizer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Emerging Therapies of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Emerging Competitive Landscape of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Nerandomilast (JASCAYD): Boehringer Ingelheim<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Product Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Developmental Activities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Development<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Trial Information<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Dazukibart: Pfizer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Efgartigimod (VYVGART): Argenx<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Anifrolumab (SAPHNELO): AstraZeneca<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">RESTEM-L (ULSC): RESTEM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Rese-cel (CABA-201): Cabaletta Bio<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Ulviprubart (ABC008): Abcuro<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Daxdilimab: Amgen<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.10<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">GLPG3667: Lakefront Biotherapeutics<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.11<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Gamgertamig (OM336): Gilead Sciences and Lakefront Biotherapeutics<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">IIM Market: 7MM Market Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Idiopathic Inflammatory Myositis Market Outlook<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Conjoint Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Idiopathic Inflammatory Myositis Market Forecast Assumptions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.5.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of IIM by Country in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.5.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Size of IIM by Therapies in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States Idiopathic Inflammatory Myositis Market\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.6.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of IIM in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.6.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Size of IIM by Therapies in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK Idiopathic Inflammatory Myositis Market\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan Idiopathic Inflammatory Myositis Market\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">14<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Unmet Needs of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">15<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">SWOT Analysis of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">16<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">KOL Views of IIM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Access and Reimbursement<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">18<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Bibliography<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">19<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Idiopathic Inflammatory Myositis Market Report Methodology<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Related Reports<\/b><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x0Jqcczc-bvpBIublnyq1mEGaEVT1AElzXdL7AwnEjU7xnaDMIGYFcmF-AwGInijz2cs9HjqL_wpafaPXpYKo5ieVRkU_zSYBDSaU_nuSlMrwzzaHYDTE0xZ_cMzaYkN6fXyQlhHra9QKiSEvIpaJ9Luz57bzPjc5QF5FqAknU6uYR2DvjikpTusDHY2XFTFn1BTkDvVz8vPvsptCrulQLyXaMR-jeMcLBXxiNDm127_svEqrRW6TdVq1xI5_fesD5O0Reda2FcioAuAhfotuA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Inflammatory Myositis Market<\/b><\/a><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast <\/b><b>\u2013 2036 <\/b>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key inflammatory myositis companies, including <b>CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfizer, Kezar Life Sciences<\/b><b>, <\/b>and others.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5v4WhvLGYzgLH9RCboV5xif63q8TuQ20paOfnB-lBVd6O2oxGKYIeJyQaEZqxNUnM5dHNJFu69ElUB_4EdhsrBMdNiF-RCdFQyzyZluf2LnXyVBu4B69-C3z7XBGAGp7AOScIZruUoSwSPvUt7H_pguKKWZKUDsd5QxQZseLUIcL_END0cWW8C4_hrARyhlv5PZsPK9LQUARdC-LJffrW96CbeMolfkEaJ-x1_q5cp_Iveagfb8K0LHX-Tb3et7WftO-D7Sej59eVoEUHRfDGg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Myositis Clinical Trial Analysis\u00a0<\/b><\/a><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Myositis Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myositis companies, including <b>GlaxoSmithKline, Corbus Pharmaceuticals, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Viela Bio, Paean Biotechnology Inc., Alexion Pharmaceuticals, Janssen Biotech, CSL Behring, Pfizer, Roche, <\/b>and others.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SrQY5cjD2aLcfyBFiB47SwYvFXV_kMd_VfG-zkmDr-VCtsa-7fn88dfElm-qTmmim0AWP-i30End96QHqQSLgtDbtuBJayGc7nzf-UZw1lLYea-1Oc7PBdNXgbB66EFNWSHpDfLE0yBEiMilYLNxWtSNsVhZg5lPYqop3XxoFURZFupBzIGtcBkxjav4eQwJSV34mdDPLqXWsAYQJmCxgRVF6Y79CTjvRMZqPXdPgEmphd5RE6uIrONlwtZj5J9TMenEeuZr8yHh___dEW3t5w==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Inclusion Body Myositis Market<\/b><\/a><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Inclusion Body Myositis<\/b><b> Market Insight, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key inclusion body myositis companies, including<b> Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, <\/b>and others.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SrQY5cjD2aLcfyBFiB47SwYvFXV_kMd_VfG-zkmDr-WtJxXLG_Uf1zszBKfVxNT2IfQYAoMnnxhw4r8Uaszk-tjhgeeFggqWj0rAFqj0LkTnmxCdZnCFICuAyZJmgck8YG5BtYZ5Pm-s7jPUigqgpVE-QB85Ksh8xpmGFihKtBynMX_ufxrH0TjLfuRLLhuoszTuCUz7VF76Zemb_AZ0uJUAXi16dYgM9dzJzZUjPW1g7cdZnTzQnxIi1fq0GGgzTdYzgtnykmjpCME3hEZVQjGSzWiaek0ES4PfmIt45Xx9FkK9gsPHIi40JseObqHI\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Inclusion Body Myositis Clinical Trial Analysis\u00a0<\/b><\/a><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Inclusion Body Myositis Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key inclusion body myositis companies, including <b>Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, <\/b>and others.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ldpv3T7E4aoaJA7mUPCDlww3AyxZjqwdBmfO4r_VDNBsnT355xP7kiPkNg0gx5vkFPEhekhKFp0rbYD7Uqs8ZxCaLr0kIlSPWkq1ySgOZIcci6rSIeM-2QtT0IqcCS7L12UHy2lscboN9dnraQHe7uZYGGG256xkc4jsIQ9cOurY2drVLlMYh7OD2MtLEIOpl9JQr6ML9RXVu6RZDmY9d8Rv2MqnhfkPLb341uivd3PbARa9m1GjelSQiapkv-MO\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Dermatomyositis Market<\/b><\/a><\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>Dermatomyositis Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dermatomyositis companies, including <b>Priovant Therapeutics, Pfizer, Argenx<\/b><b>, <\/b>and others.<\/p>\n<p align=\"justify\" style=\"text-align:justify;\"><b>About\u00a0DelveInsight<\/b><\/p>\n<p align=\"justify\" style=\"text-align:justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<b>.<\/b><\/p>\n<pre>CONTACT: Contact Us\n\nShruti Thakur\u00a0\n\ninfo@delveinsight.com\u00a0\n\n+14699457679\n\nwww.delveinsight.com<\/pre>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/Y2EzODFhN2EtOGI0MS00Zjc0LWEwZjEtZGM5MGQ4NjNlYWE0LTEyMDQ5MzgtMjAyNi0xMS0xMC1lbg==\/tiny\/DelveInsight-Business-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&#8217;s report sizes the Idiopathic Inflammatory Myositis market at USD 714 million across the 7MM in 2025, with a significant 16.8% CAGR forecast through 2036. This growth is driven by the high unmet medical need, increasing disease awareness, advancements in diagnostic capabilities, and the growing focus on developing targeted therapies to address disease heterogeneity and [&#8230;]\n","protected":false},"author":1,"featured_media":90493,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-90492","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"DelveInsight&#8217;s report sizes the Idiopathic Inflammatory Myositis market at USD 714 million across the 7MM in 2025, with a significant 16.8% CAGR\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T19:23:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-11T02:11:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight\",\"datePublished\":\"2026-11-10T19:23:00+00:00\",\"dateModified\":\"2026-11-11T02:11:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/\"},\"wordCount\":2443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/\",\"name\":\"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-11-10T19:23:00+00:00\",\"dateModified\":\"2026-11-11T02:11:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/","og_locale":"en_US","og_type":"article","og_title":"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight","og_description":"DelveInsight&#8217;s report sizes the Idiopathic Inflammatory Myositis market at USD 714 million across the 7MM in 2025, with a significant 16.8% CAGR","og_url":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-11-10T19:23:00+00:00","article_modified_time":"2026-11-11T02:11:43+00:00","og_image":[{"width":800,"height":420,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight","datePublished":"2026-11-10T19:23:00+00:00","dateModified":"2026-11-11T02:11:43+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/"},"wordCount":2443,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/","url":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/","name":"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-11-10T19:23:00+00:00","dateModified":"2026-11-11T02:11:43+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/idiopathic-inflammatory-myositis-market-set-for-strong-growth-at-16-8-cagr-through-2036-driven-by-rising-demand-for-targeted-therapies-delveinsight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=90492"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90492\/revisions"}],"predecessor-version":[{"id":90494,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90492\/revisions\/90494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/90493"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=90492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=90492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=90492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}